During 2018 Q4 the big money sentiment increased to 1.4. That’s change of 0.15, from 2018Q3’s 1.25. 18 investors sold all, 44 reduced holdings as Intercept Pharmaceuticals, Inc. ratio increased. 47 grew stakes while 40 funds amassed stakes. Funds hold 19.17 million shares thus 5.26% more from 2018Q3’s 18.21 million shares.
Zurcher Kantonalbank (Zurich Cantonalbank) stated it has 1,416 shs or 0% of all its holdings. Pathstone Family Office Ltd Liability Corporation reported 40 shs. Ameritas stated it has 0.01% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Laurion Capital Mgmt L P has 0.43% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 239,533 shs. First Tru Advsr Ltd Partnership holds 981,483 shs. Guggenheim Cap Ltd Llc has invested 0.02% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Public Employees Retirement Association Of Colorado owns 3,548 shs. Fred Alger Mngmt stated it has 7,000 shs or 0% of all its holdings. Ontario – Canada-based Canada Pension Plan Inv Board has invested 0.01% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Profund Limited Liability holds 6,047 shs. Alliancebernstein Ltd Partnership holds 69,470 shs. Moreover, Credit Suisse Ag has 0.01% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Biondo Invest Advsrs holds 0.61% or 20,025 shs in its capital. Jpmorgan Chase And Co owns 1.24 million shs. Hudock Cap Ltd Liability Company owns 0% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 50 shs.

It was recorded an increase on Intercept Pharmaceuticals Inc (NASDAQ:ICPT)’s short interest with 13.34%. It was announced in April by FINRA the 3.23M short interest on ICPT. The 2.85 million previous shares are up with 13.34%. Former ICPT’s position will need 5 days to restore. It has 692,000 average volume. Intercept Pharmaceuticals Inc’s short interest float is 14.19%.

The stock increased 1.19% or $1.38 during the last trading session, reaching $117.03.Currently Intercept Pharmaceuticals, Inc. is uptrending after 77.42% change in last April 7, 2018. ICPT has 726,073 shares volume. The stock outperformed the S&P500 by 73.05%.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases.The firm is worth $3.48 billion. The Company’s lead product candidate is obeticholic acid , a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).Currently it has negative earnings. The firm is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Ratings Coverage

A total of 14 analysts rate Intercept Pharmaceuticals (NASDAQ:ICPT) as follows: 11 “Buy”, 2 “Hold” and 1 “Sell”. Тherefore 79% are bullish. (NASDAQ:ICPT) has 31 ratings reports on Apr 7, 2019 according to StockzIntelligence. On Wednesday, February 20 the company was maintained by RBC Capital Markets. The company rating was maintained by Robert W. Baird on Tuesday, February 19. On Thursday, January 24 the company was upgraded by Needham. On Monday, January 14 the firm has “Buy” rating given by Laidlaw. On Tuesday, February 19 the rating was maintained by FBR Capital with “Buy”. On Tuesday, February 19 Roth Capital maintained the shares of ICPT in report with “Buy” rating. On Monday, February 4 the firm has “Strong Buy” rating given by Raymond James. On Tuesday, February 19 Wedbush maintained the shares of ICPT in report with “Outperform” rating. On Monday, November 19 the firm has “Outperform” rating by Oppenheimer given. In Tuesday, February 19 report Cantor Fitzgerald maintained the stock with “Buy” rating.

For more Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) news released recently go to: Nasdaq.com, Seekingalpha.com, Benzinga.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “Notable Wednesday Option Activity: ZNGA, SPSC, ICPT – Nasdaq” released on February 13, 2019, “Genfit And The NASH Education Program: The Race To Inform – Seeking Alpha” on April 05, 2019, “36 Stocks Moving In Tuesday’s Pre-Market Session – Benzinga” with a publish date: March 19, 2019, “2 Biotechs With Big Dates in April – Nasdaq” and the last “Novartis (NVS) to Acquire Subsidiary of IFM Therapeutics – Nasdaq” with publication date: April 01, 2019.